Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors | EMBO Molecular Medicine
Translating current basic research into future therapies for neurofibromatosis type 1 | British Journal of Cancer
EU approves Koselugo for treatment of plexiform neurofibromas
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib | SpringerLink
The Discovery of Selumetinib for Kids with NF1 - NCI
A melanoma drug shows promise for NF1 plexiforms | Children's National
Selumetinib in Children with Inoperable Plexiform Neurofibromas | NEJM
Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors | EMBO Molecular Medicine
In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1 | National Institutes of Health (NIH)
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review - ESMO Open
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | Semantic Scholar
,%20Glioma,%20Low%20Grade%20Glioma%20(LGG),%20Neurofibroma,%20Neurofibromatosis%201,%20Visual%20Pathway%20Glioma:%0A%0ASelumetinib%20Sulfate%20for%20Watson%20Syndrome.png?md=1 "Selumetinib Sulfate for Watson Syndrome Clinical Trial | Power")
Selumetinib Sulfate for Watson Syndrome Clinical Trial | Power
NIH Reports Successful Phase II Results in Pediatric Neurofibromatosis Study | BioSpace
NIH trial shows selumetinib shrinks tumors, provides clinical benefit for children with NF1 | Healthcare Purchasing News
MOA | Study Design | KOSELUGO® (selumetinib) 10 mg & 25 mg capsules | For HCPs
Clinical and Experimental Pediatrics
Selumetinib Granted Orphan Drug Designation by the FDA for NF1 | Children's Tumor Foundation
AZ's Koselugo scores regulatory nod for children with rare neurofibroma < Pharma < 기사본문 - KBR
Current state of MEK inhibitor trials in neurofibromatosis type 1 | Download Scientific Diagram
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | Semantic Scholar
Phase 2 Trial Shows Selumetinib Shrinks Nerve Tumors in Children With NF1 | Technology Networks
Children's Inn Residents Participate in NCI's Center for Cancer Research Trial That Shrinks Tumors in Children with NF1 | The Children's Inn at NIH
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review - ESMO Open
Selumetinib enhances the anti-migratory effects of LDN-193189 in MPNST... | Download Scientific Diagram
